1. In Vivo

Amgen’s Surprise Aflibercept Launch Shakes Up US Biosimilars In 2024

As Market Approaches Tenth Anniversary Of First Biosimilars Approval And Launch

 
• By Dave Wallace

As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.

In March 2025, the US biosimilars market will celebrate ten years since the first biosimilar received approval from the US Food and Drug Administration, under the Biologics Price Competition and Innovation Act framework that was first introduced back in 2010.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Growth

More from Market Access